Tempus Labs

Chicago, Illinois, US  All United States companies → — Founded 2015
Point-of-Care Diagnostics Specialty-Focused AI
Laboratory Medicine Oncology Pathology
Lab & Diagnostics Oncology AI
Public (Nasdaq: TEM) — $1.3 billion (private funding before IPO)
Claim this company

Products

xT CDx
Tempus Labs
Lab & Diagnostics
Tempus xT CDx is an FDA-approved, 648-gene Next Generation Sequencing (NGS) test for comprehensive molecular profiling of solid malignant tumors, including companion diagnostic claims for colorectal cancer.
Contact for pricing; varies by insurance coverage and financial assistance.

See all 1 product →

About Tempus Labs

Tempus AI (formerly Tempus Labs) is a leading health technology company that leverages artificial intelligence (AI) and a vast library of multimodal clinical and molecular data to advance precision medicine. For physicians, Tempus provides “Intelligent Diagnostics” that aim to make laboratory tests more accurate, tailored, and personal, enabling data-driven decisions at the point of care. Their platform integrates genomic sequencing services, molecular and therapeutic data, and real-time outcome and response data from electronic health records to offer comprehensive insights for personalized treatment protocols.

Initially focused on oncology, Tempus has expanded its offerings to include neuropsychiatry (e.g., pharmacogenomic testing for depression), cardiology (solutions for undiagnosed or undertreated cardiovascular disease), infectious disease, and radiology. They also provide clinical trial matching services, using AI to connect patients with suitable trials and accelerate enrollment, and offer research solutions for life sciences companies to aid in drug discovery and development.

What Physicians Need to Know

Precision Medicine & Oncology Focus
Tempus specializes in applying AI to precision medicine, particularly in oncology, genomics, and personalized cancer treatment. They offer comprehensive genomic sequencing (DNA and RNA) to identify mutations and recommend optimal therapies or clinical trials.
Multimodal Data Platform
They have built one of the world's largest libraries of multimodal clinical and molecular data, integrating genomic, clinical, imaging, and pathology data from millions of patients.
AI-Powered Diagnostics & Insights
Tempus develops 'Intelligent Diagnostics' that leverage AI, including generative AI and Large Language Models (LLMs), to rapidly analyze vast volumes of patient records and unstructured data, enhancing lab test accuracy and personalization.
Accelerated Clinical Trial Matching
Their AI-driven platforms, such as the TIME Trial Program and Next Trials, rapidly match patients to relevant clinical trials based on their molecular profiles and clinical data, significantly accelerating enrollment.
Care Pathway Intelligence
Platforms like Tempus Next provide AI-enabled care pathway intelligence, identifying care gaps and delivering near real-time alerts to clinicians to help ensure adherence to clinical guidelines.
Key Differentiator: Multimodal Data Integration at Scale
Unlike many competitors, Tempus uniquely links genomic data with comprehensive clinical information (EHRs, imaging, pathology, outcomes) at a massive scale, encompassing over 40 million patient records with 4 million paired with sequencing data. This provides a holistic patient view and fuels robust AI model training.
Key Differentiator: Generative AI & LLM Capabilities
Extensive use of generative AI and LLMs allows for rapid analysis of unstructured data (clinical notes, pathology reports), natural language-based cohort building, and instant insight generation.
Technology Stack: AI/ML & NLP
Core technologies include advanced Artificial Intelligence, Machine Learning, and Natural Language Processing (NLP) for data abstraction, cohort building, and transforming unstructured clinical data into queryable formats.
Technology Stack: Big Data & Genomics
Manages one of the world's largest multimodal data libraries (350+ petabytes) and utilizes high-throughput DNA and RNA genomic sequencing.
Technology Stack: Data Analytics & Visualization
Leverages tools like Lens Analytical Apps, Lens Workspaces (with R and Jupyter Notebooks), Looker, and Tableau for data exploration, refinement, and visualization.
Physician Tip

For physicians, Tempus Labs stands out by empowering personalized treatment decisions through the integration of unique molecular profiles with vast clinical data and AI-driven insights, moving beyond a 'one-size-fits-all' approach. The platforms, such as Tempus One and Hub, streamline workflows by integrating seamlessly into existing EHR systems, reducing administrative burden and providing direct access to comprehensive, actionable insights and detailed genomic reports. This includes contextualized data based on guidelines like MSK OncoKB, NCCN Guidelines, and ASCO Guidelines. Furthermore, Tempus significantly accelerates clinical trial matching, connecting patients to cutting-edge therapies in days rather than months. For physician-researchers, tools like Tempus Lens enable the easy construction of precise patient cohorts and rapid insight generation from unstructured data.

Tempus Labs offers extensive integration capabilities with major Electronic Health Record (EHR) systems, including Epic (with specific mention of Epic Genomics Module and Aura network), Cerner, CureMD, Meditech, NextGen, Veradigm (formerly Allscripts), Flatiron's OncoEMR, and iKnowMed. These integrations are designed to be seamless, bringing genomic and AI-driven insights directly into the physician's workflow, thereby improving the speed and efficiency of data exchange and clinical decision-making.

Products by Tempus Labs

1 product in the directory

xT CDx
Tempus Labs
Lab & Diagnostics
Tempus xT CDx is an FDA-approved, 648-gene Next Generation Sequencing (NGS) test for comprehensive molecular profiling of solid malignant tumors, including companion diagnostic claims for colorectal cancer.
Contact for pricing; varies by insurance coverage and financial assistance.

What the Web Says

Tempus Labs is a biotechnology company that utilizes AI to analyze clinical and molecular data for personalized healthcare treatments, primarily in oncology, but also expanding to neurology/psychiatry, cardiology, and infectious diseases. Employee reviews are mixed, with some praising the mission-driven work and collaborative environment, while others highlight issues with management, work-life balance, and compensation. Product reviews, particularly for their genetic testing, also show a range of experiences, with some finding the results helpful and others encountering difficulties with interpretation and customer service.

Overall: Mixed

Strengths

  • Impactful and mission-driven work in healthcare innovation and AI.
  • Collaborative teams and knowledge sharing.
  • Opportunities for continuous development of technical and scientific skills.
  • Helpful for mutation-guided precision medicine.
  • Offers financial assistance for testing.
  • Strong partnerships with major pharmaceutical companies.

Limitations

  • Disorganized and toxic management.
  • Lack of work-life balance.
  • Poor compensation and benefits.
  • Difficult to navigate and interpret genetic test results for some users.
  • Issues with customer service and billing for genetic testing.
  • Some comparisons of their assay being inferior to competitors like Foundation Medicine.

Based on reviews from: Reddit, Nebula Genomics, Capterra, Indeed.com, Built In, Goodfirms

Last updated: 2026-07-19

Videos

News, demos, and interviews about Tempus Labs.

Loading videos...

Videos load interactively. If none appear, search YouTube for Tempus Labs →

View all on YouTube

Press & Coverage

Business Wire
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
Tempus highlighted the results of the Articulate Pro study, published in Nature Digital Medicine, which evaluated the use of AI to assist pathologists in prostate biopsy reporting within the UK National Health Service. The study demonstrated that AI-assisted review improved diagnostic consistency and reduced laboratory workloads.
2026-07
Tempus News
Tempus to Report Second Quarter 2026 Financial Results on July 30
Tempus AI, Inc. announced it will report its second quarter 2026 financial results on Thursday, July 30, 2026, and will host a conference call and webcast.
2026-07
Tempus News
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
Tempus AI, Inc. announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, a rare and aggressive cancer.
2026-06
Tempus News
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
Tempus announced the successful multi-center validation of its FDA-cleared ECG-AF software for predicting the one-year risk of atrial fibrillation, with results published in Heart Rhythm.
2026-06
Tempus News
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
Tempus AI, Inc., Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center launched a digital pathology IMS Open-Source Consortium to advance precision medicine.
2026-06
Investing.com
Tempus wins FDA OK for tumor-only xT CDx assay
Tempus AI, Inc. received FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform, making it the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling.
2026-05
Tempus
Navigating the new frontier: How regulatory leadership in AI development and commercialization can accelerate precision medicine
This article discusses Tempus's robust portfolio of regulated products, including the xT CDx assay and FDA 510(k) cleared AI algorithms in cardiology, highlighting how regulatory milestones build clinical trust and drive adoption of new AI tools.
2026-05
Tempus News
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
Tempus AI, Inc. announced an expanded, multi-year collaboration with Gilead Sciences, Inc. to accelerate the discovery and development of precision medicine biomarkers and support Gilead's oncology pipeline.
2026-04

Frequently Asked Questions

Tempus Labs provides AI-powered genomic testing, including xT, xR, xE, and xF/xF+, alongside digital pathology and clinical trial matching services through its TIME Network. For clinical decision support and administrative tasks, they offer AI-enabled assistants like Tempus One, which integrates with EHRs to summarize patient history, assist with documentation, and facilitate clinical trial matching.
Tempus Labs is committed to maintaining the privacy and security of Protected Health Information (PHI) in compliance with HIPAA, utilizing access controls, monitoring, and auditing features. For research purposes, data is de-identified according to HIPAA standards. Some of their diagnostic products, such as Tempus xR IVD, have received U.S. FDA 510(k) clearance.
Tempus Labs accepts all insurance plans for its genomic testing services and offers a patient financial assistance program for those in need. For uninsured or international patients, a self-pay option is available. While specific institutional pricing varies, genomic tests can range from $2,500 to $4,000, and they also engage in multi-year data licensing agreements with partners.
Tempus Labs offers comprehensive customer support via phone and email, with a team available Monday through Friday from 7 am to 7 pm CST. They provide dedicated integration experts to facilitate seamless EHR connectivity, ensuring efficient ordering and delivery of results directly within existing clinical workflows.
Tempus Labs collaborates extensively with academic medical centers, over 50% of U.S. oncologists, and 95% of top pharmaceutical oncology companies. These partnerships, including those with institutions like the University of Washington and companies like AstraZeneca and Merck, aim to accelerate precision medicine, enhance clinical trial matching, and provide clinicians with data-driven insights for personalized patient care.
Tempus AI recently went public in June 2024 and reported substantial revenue growth, with a 2026 revenue guidance of approximately $1.59 billion, indicating a strong financial trajectory. Their long-term vision is to evolve into an 'operating system' for data-driven care, continuously expanding their AI applications, genomic testing, and data services beyond oncology and into international markets.
Tempus Labs is a leader in EHR integrations, boasting over 600 direct data connections across more than 5,000 healthcare institutions. Their platforms integrate with major EHR systems like Epic (including its Genomics Module and Aura), Cerner, Meditech, and Flatiron's OncoEMR, enabling seamless electronic ordering, order tracking, and discrete genomic data delivery directly into clinical workflows.

Investors

Who's funded Tempus Labs.

Deerfield Catalyst
T1
New York, United States
Deerfield Catalyst is the early-stage and incubation arm of Deerfield Management, the New York healthcare-only investment platform that manages billions across public…

Related Companies

QuickIntell
Chicago, IL, USA

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief
Kulpsville, PA

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed (Niedersächsisches Zentrum für KI und Kausale Methoden in der Medizin)
Hannover, Germany (Lower Saxony region)

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm
Berkeley, United States and London, United Kingdom. European office in Barcelona, Spain and Gothenburg, Sweden.

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA
London, UK

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Fraunhofer-Gesellschaft (Fraunhofer AICOS) / PALMX APPS LTD / Skin Analytics
London, United Kingdom

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
Suggest an Edit →
AI Tool Finder
AI-powered search. Results may not be comprehensive.